Gene Transfer Technologies Market is expected to reach US$ 8.74 Billion by 2033 | Qiagen, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., MaxCyte, Cytiva

Global gene transfer technologies market size reached US$ 3.78 Billion in 2024 from US$ 3.47 Billion in 2023 and is expected to reach US$ 8.74 Billion by 2033, growing at a CAGR of 9.8% during the forecast period 2025-2033.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/gene-transfer-technologies-market?sg

Key Developments in Gene Transfer Technologies - 2025

✅ (Feb 2025) - Bluebird Bio acquired by private equity

➠ Carlyle Group and SK Capital Partners are acquiring Bluebird Bio, a struggling gene therapy company.

✅ (June 16, 2025) - Eli Lilly to acquire Verve Therapeutics

➠ Eli Lilly is buying Verve Therapeutics for up to US$ 1.3 billion.

➠ Verve's lead program, VERVE-102, is a CRISPR-based base‐editing therapy targeting PCSK9 (for cholesterol reduction) and is delivered via a lipid nanoparticle (LNP) vehicle.

✅ (Aug 21, 2025) - Gilead / Kite Pharma acquires Interius BioTherapeutics

➠ Kite Pharma (a Gilead unit) is acquiring Interius BioTherapeutics for US$ 350 million.

Interius has a novel in‐vivo delivery platform: instead of extracting T‐cells, modifying them, and reinfusing (traditional CAR‐T), they deliver DNA directly into patient cells via intravenous infusion.

✅ (H1 2025) - Large vector & delivery‐platform deals (from DealForma report)

➠ AbbVie agreed to acquire Capstan for up to US$ 2.1 billion.

➠ Capstan's value lies in its targeted LNP (tLNP) platform for in vivo RNA delivery, and its pipeline (including CAR‐T) using that system.

➠ Vertex Pharmaceuticals partnered with Orna Therapeutics (January 2025) on gene‐editing therapies for sickle cell disease (SCD) and transfusion‐dependent β-thalassemia (TDT). The deal: US$ 65 million upfront, up to US$ 635 million in milestones, + options.

➠ Eli Lilly (again) licensed a Sangamo AAV capsid ("STAC‐BBB") for central nervous system (CNS) gene therapy, with US$ 18 million upfront + up to US$ 1.4 billion in milestones.

➠ Nippon Shinyaku secured rights to Regenxbio's RGX-121/111 (AAV-based) for Hunter and Hurler syndromes: US$ 110 m upfront, plus milestones/royalties up to US$ 700 m.

✅ (July 2025) - First commercial-scale manufacturing for a rare-disease AAV therapy

➠ According to a market‐report summary, Myrtelle, Inc. began commercial-stage manufacturing in July 2025 for its rAAV gene therapy for Canavan disease.

✅ (2025) - Pipeline strength in gene‐cell therapy by major players

➠ Bayer, via its viral‐vector arm Viralgen (from AskBio), is pushing its pipeline in Parkinson's, oncology, rare diseases, and more using advanced gene‐cell therapy modalities.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/gene-transfer-technologies-market?sg

Key Market Drivers:

✅ Rising demand for gene & cell therapies: The increasing development and adoption of personalized medicine (especially in oncology and rare genetic diseases) is fueling strong demand for safe and efficient gene delivery platforms.

✅ Regulatory momentum: More regulatory approvals for gene therapies is validating the commercial potential of gene transfer technologies, encouraging more R&D investment.

✅ Technological innovation in delivery systems: Advances in viral vectors (e.g., AAV, lentivirus) and non-viral methods (like lipid nanoparticles, electroporation) are improving efficiency, specificity, and safety.

✅ Growing R&D and funding: Biotech companies, academic institutions, and contract manufacturers are heavily investing in scalable manufacturing for gene delivery tools especially as gene therapy pipelines grow.

✅ Broader applications: Gene transfer is not just for therapy - it's being used in vaccine development, biomanufacturing, and functional genomics.

Regional Share & Trends:

➠ North America: Leads the global market, driven by strong biotech infrastructure, high R&D spending, and favorable regulation.

➠ Europe: Significant market presence, supported by established pharmaceutical companies and well-developed research institutions.

➠ Asia-Pacific: The fastest-growing region. Growth is stimulated by increasing investments in biotech (especially in China, India, Japan, South Korea), a large patient population, and rising government support.

➠ Latin America & Middle East/Africa: Smaller market shares currently (e.g., Latin America ~4-5%, Middle East & Africa ~3-4%) but growing due to improving healthcare infrastructure and increasing biotech activity.

Segments Covered in the Gene Transfer Technologies Market:

By Product Type (Reagents, Kits and Assays, Consumables, Instruments, and Others)

By Mode (Viral Vectors, Non-Viral Vectors, and Physical Methods)

By Method (In Vivo, Ex Vivo, and In Vitro)

By Application( Therapeutic Applications, Research Applications, and Others)

By End-User (Pharmaceutical and Biotechnology Companies, Academic & Research Institutes, and Others)

Regional Analysis for Gene Transfer Technologies Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=gene-transfer-technologies-market?sg

Major Key Players: Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Qiagen, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., MaxCyte, and Cytiva.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription?sg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.